Winton Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.27M | Buy |
+135,800
| New | +$3.55M | 0.11% | 227 |
|
|
2026
Q1 | – | Sell |
-17,241
| Closed | -$429K | – | 1322 |
|
|
2025
Q4 | $429K | Sell |
17,241
-545,667
| -97% | -$13.8M | 0.01% | 669 |
|
|
2025
Q3 | $14.3M | Buy |
+562,908
| New | +$13.9M | 0.54% | 31 |
|
|
2024
Q2 | – | Sell |
-21,000
| Closed | -$583K | – | 694 |
|
|
2024
Q1 | $583K | Buy |
+21,000
| New | +$583K | 0.04% | 452 |
|
|
2023
Q2 | – | Sell |
-100,419
| Closed | -$4.1M | – | 1038 |
|
|
2023
Q1 | $4.1M | Buy |
100,419
+35,939
| +56% | +$1.55M | 0.25% | 61 |
|
|
2022
Q4 | $3.3M | Buy |
+64,480
| New | +$3.09M | 0.22% | 86 |
|
|
2022
Q3 | – | Sell |
-36,753
| Closed | -$1.93M | – | 1053 |
|
|
2022
Q2 | $1.93M | Buy |
36,753
+6,600
| +22% | +$336K | 0.1% | 275 |
|
|
2022
Q1 | $1.56M | Buy |
30,153
+8,740
| +41% | +$453K | 0.08% | 323 |
|
|
2021
Q4 | $1.26M | Sell |
21,413
-6,774
| -24% | -$336K | 0.08% | 383 |
|
|
2021
Q3 | $1.21M | Sell |
28,187
-18,554
| -40% | -$822K | 0.07% | 404 |
|
|
2021
Q2 | $1.83M | Sell |
46,741
-17,528
| -27% | -$682K | 0.1% | 220 |
|
|
2021
Q1 | $2.33M | Buy |
64,269
+46,951
| +271% | +$1.67M | 0.13% | 99 |
|
|
2020
Q4 | $637K | Sell |
17,318
-14,799
| -46% | -$543K | 0.05% | 663 |
|
|
2020
Q3 | $1.12M | Sell |
32,117
-79,552
| -71% | -$2.79M | 0.04% | 776 |
|
|
2020
Q2 | $3.46M | Buy |
+111,669
| New | +$3.79M | 0.09% | 392 |
|
|
2019
Q4 | – | Sell |
-596,037
| Closed | -$20.3M | – | 1723 |
|
|
2019
Q3 | $20.3M | Buy |
596,037
+413,190
| +226% | +$15M | 0.24% | 136 |
|
|
2019
Q2 | $7.51M | Buy |
182,847
+165,373
| +946% | +$6.57M | 0.15% | 195 |
|
|
2019
Q1 | $704K | Sell |
17,474
-133,879
| -88% | -$5.36M | 0.01% | 453 |
|
|
2018
Q4 | $6.27M | Buy |
151,353
+134,274
| +786% | +$5.57M | 0.14% | 250 |
|
|
2018
Q3 | $714K | Sell |
17,079
-12,649
| -43% | -$487K | 0.02% | 493 |
|
|
2018
Q2 | $1.02M | Sell |
29,728
-8,965
| -23% | -$306K | 0.03% | 428 |
|
|
2018
Q1 | $1.3M | Buy |
38,693
+10,314
| +36% | +$355K | 0.04% | 420 |
|
|
2017
Q4 | $975K | Sell |
28,379
-29,106
| -51% | -$992K | 0.03% | 411 |
|
|
2017
Q3 | $1.95M | Sell |
57,485
-37,886
| -40% | -$1.22M | 0.06% | 334 |
|
|
2017
Q2 | $3.04M | Sell |
95,371
-102,686
| -52% | -$3.24M | 0.09% | 227 |
|
|
2017
Q1 | $6.43M | Buy |
198,057
+8,867
| +5% | +$280K | 0.17% | 163 |
|
|
2016
Q4 | $5.83M | Buy |
189,190
+64,748
| +52% | +$1.98M | 0.19% | 154 |
|
|
2016
Q3 | $4M | Sell |
124,442
-583,058
| -82% | -$19.5M | 0.07% | 249 |
|
|
2016
Q2 | $23.6M | Sell |
707,500
-871,661
| -55% | -$27.8M | 0.39% | 99 |
|
|
2016
Q1 | $44.4M | Sell |
1,579,161
-268,783
| -15% | -$7.68M | 0.48% | 74 |
|
|
2015
Q4 | $56.6M | Sell |
1,847,944
-310,339
| -14% | -$9.76M | 0.5% | 62 |
|
|
2015
Q3 | $64.3M | Buy |
2,158,283
+983,336
| +84% | +$31.5M | 0.51% | 45 |
|
|
2015
Q2 | $37.4M | Sell |
1,174,947
-75,554
| -6% | -$2.46M | 0.34% | 106 |
|
|
2015
Q1 | $41.3M | Sell |
1,250,501
-129,152
| -9% | -$4.11M | 0.33% | 110 |
|
|
2014
Q4 | $40.8M | Sell |
1,379,653
-1,190,688
| -46% | -$34.1M | 0.5% | 47 |
|
|
2014
Q3 | $72.1M | Sell |
2,570,341
-683,943
| -21% | -$19.2M | 0.52% | 38 |
|
|
2014
Q2 | $91.6M | Buy |
+3,254,284
| New | +$92.8M | 0.62% | 12 |
|
Other funds holding PFE
Winton Group's PFE Position: Q2 2026 in Review
Winton Group opened a new position in Pfizer (PFE) in Q2 2026: 135,800 shares worth $3.27M. The stake represents 0.11% of the portfolio and ranks #227 among its holdings. This is a return to the name: Winton Group previously reported a position in PFE as recently as Q4 2025.
Winton Group first reported a position in PFE in Q2 2014 and has held it in 37 quarters since. The position peaked at $91.6M in Q2 2014. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Winton Group held 135,800 shares of Pfizer worth $3.27M as of Q2 2026.
- Pfizer was a new Winton Group position in Q2 2026.
- Pfizer made up 0.11% of Winton Group's portfolio in Q2 2026, its #227 holding.
- Winton Group first reported a position in Pfizer in Q2 2014 and has held it in 37 quarters since.
- Winton Group's Pfizer position peaked at $91.6M in Q2 2014.
- 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.